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Abstract
Objective: Rates of vertical HIV transmission between
mother and child are low, allowing many HIV positive wom-
en to have children with near impunity. In this study, data
from the Swiss Mother and Child HIV Cohort Study were
used to describe maternal characteristics and their association
with pregnancy outcomes in HIV positive women.
Study design: HIV positive women were followed prospec-
tively during their pregnancies and deliveries by anonymous
questionnaires between January 2003 and October 2008.
Adverse pregnancy outcomes included preterm delivery, pre-
eclampsia and gestational diabetes mellitus.
Results: This study included 266 HIV positive women, of
which 67 (25.2%) were first diagnosed with HIV during
pregnancy. Thirty percent (ns80) of the women had preg-
nancy complications after 24 weeks of gestation. Preterm
delivery was noted in 72 (27%) patients. Other complications
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included preeclampsia (ns7; 2.6%) and gestational diabetes
(ns7; 2.6%). Older maternal age was the only risk factor
associated with adverse pregnancy outcomes (adjusted odds
ratio: 1.06, 95% confidence interval 1.01–1.12, Ps0.02).
Conclusions: HIV positive women, especially with advanced
maternal age, have high-risk pregnancies and should be mon-
itored as in an interdisciplinary setting. The preponderance
of initial HIV diagnosis during pregnancy confirms the
importance of HIV screening in pregnant women.
Keywords: HIV; maternal age; pregnancy; preterm delivery.
Introduction
Heterosexual women of childbearing age represent the fastest
growing risk-group for HIV infection w33x and several stud-
ies have shown an increasing prevalence of HIV infection in
European women in their reproductive years w12x. Mean-
while, the widespread use of combined antiretroviral treat-
ment (cART) among HIV infected women has led to a
dramatic decrease in the rate of mother-to-child transmission
(MTCT) in Europe to around 1% w1, 5, 10, 11x. Because of
cART therapy, HIV positive people can live healthier lives
with almost normal life expectancies. This reinforces the
desire of HIV positive women to have their own children
and plan their pregnancies. However, HIV positive women
are still confronted with the fear of vertical transmission of
HIV as well as the possible risk of an adverse pregnancy
outcome namely, preterm delivery, preeclampsia or gesta-
tional diabetes. Little is known regarding prevalence and
maternal risk factors of adverse pregnancy outcomes in HIV
positive women. Some authors reported an increased risk of
preterm delivery, particularly if a regimen containing prote-
ase inhibitors is administered before and during pregnancy
wadjusted odds ratio (aOR) 2.6x w1, 7, 18x. Many studies
addressing pregnancy in HIV positive women focus mainly
on the type of antiretroviral therapy (ART) administered
w4, 9, 13, 19, 30x.
However, maternal age, ethnicity, smoking habits, co-
infections and obesity may influence pregnancy outcome in
HIV negative women w17, 20, 21, 28, 32x. The goal of the
present study was therefore to analyse maternal characteris-
tics and delivery outcomes of HIV positive women who seek
prenatal treatment in Switzerland. We hypothesised that
maternal characteristics and co-morbidities do influence
pregnancy outcome, even under optimal ART.
354 Aebi-Popp et al., Pregnancy outcome and HIV
Article in press - uncorrected proof
Table 1 Maternal characteristics.
Characteristic Value (ns266)
Maternal age at delivery, mean (SD) 32 (5.4)
Ethnicity, n (%)
Caucasian 92 (34.6)
Non-White 174 (65.4)
Mode of acquisition, n (%)
Heterosexual sex 226 (85.0)
Injection drug use 29 (10.9)
Other 11 (4.1)
HIV diagnosis during pregnancy, n (%) 67 (25.2)
Time since positive HIV-test (years), median 5.2 (2.7–9.6)
(IQR)
HIV-1 RNA viral load at delivery (copies/mL),
n/244 (%)
-50 192 (78.7)
50–399 33 (13.5)
G400 19 (7.8)
CD4 cell count at delivery (cells/mL), n/210 (%)
-200 15 (7.1)
200–349 63 (30.0)
G350 132 (62.9)
ART naive, n (%)
At conception 94 (35.5)
At delivery 5 (1.9)
Type of conception, n (%)
Spontaneous 235 (88.3)
Infertility treatment 3 (1.1)
Artificial insemination 2 (0.8)
Self insemination 16 (6.0)
Unknown 10 (3.8)
Mode of delivery
Caesarean section
Elective 180 (67.7)
Secondary 56 (21.1)
Vaginal
Spontaneous 21 (7.9)
Instrumental 7 (2.6)
Duration of pregnancy, n (%)
-37 weeks 72 (27.1)
)37 weeks 194 (73.0)
SDsstandard deviation, IQRsinterquartile range, ARTsantiretro-
viral therapy.
Methods
The Swiss Mother and Child HIV Cohort Study (MoCHiV) is an
ongoing prospective observational study. In 2003, MoCHiV was
fully integrated into the Swiss HIV Cohort Study (SHCS) and new
questionnaires were introduced, containing more information about
maternal characteristics, pregnancy and delivery complications. The
anonymously collected data include demographic information, clin-
ical and medical history as well as follow-up data. Written informed
consent was obtained in all cases and ethical approval for the study
was granted.
All pregnant women enrolled in the SHCS between January 2003
and October 2008 who agreed to participate in MoCHiV were
included in the study. Maternal information included results of
clinical and laboratory investigations, information about ART, intra-
venous drug abuse, alcohol abuse, smoking habits and sociodemo-
graphic information. Gestational age was defined as the time
between the first day of the last menstrual period and the day of
delivery. Preterm delivery was defined as duration of pregnancy
between 34 weeksq0 days and 37 weeksq0 days of gestation and
very preterm delivery between 24q0 and 34q0 weeks’ gestation.
A shortened cervix was defined as a cervical length -25 mm,
measured by transvaginal ultrasound. Intrauterine growth retardation
(IUGR) was defined as an estimated fetal weight under the 5th per-
centile as measured by transabdominal ultrasound. Maternal CD4q
cell counts (cells/mL) and HIV RNA level (RNA-copies/mL) near-
est to the time of delivery were used in the analyses. CD4q cell
counts were categorised as -200, 200–499 and )500 cells/mL.
Screening for gestational diabetes mellitus was performed between
24 and 28 weeks’ gestation with a 50-g glucose challenge test. Cae-
sarean section before the onset of labour and rupture of membranes
was categorized as elective and all others as secondary/emergency.
In this period of the study, women were offered an elective caesa-
rean section according to the Swiss guidelines. Vaginal delivery was
offered in some centres since 2006 for women with undetectable
viral load and without co-infections. Newborns were tested for HIV
at one and six months after delivery with two different tests (antigen
p24 and DNA PCR) at each time. Once all tests were found to be
negative, the child was considered as non-infected.
Categorical data were analysed by calculating percentages and
x2-tests. Means, medians, standard deviations (SD), and interquar-
tile ranges (IQR) were calculated for continuous variables. Multi-
variable logistic regression was used to study the association
between maternal factors and adverse pregnancy outcome. Adverse
pregnancy outcome was defined as occurrence of any of the follow-
ing conditions: preterm delivery, cervical shortening, premature rup-
ture of membranes (PROM), preeclampsia or arterial hypertension,
vaginal bleeding and gestational diabetes. Explanatory variables
included in the model were ethnicity (Caucasian vs. non-Caucasian),
maternal cigarette smoking, drug use, co-infections (hepatitis B,
hepatitis C, syphilis), maternal BMI, cART regimen, CD4q cell
count, duration of HIV infection and maternal age. Time varying
variables were included at the time of conception if not otherwise
stated. P-0.05 were defined as statistically significant.
Results
Overall, 269 pregnancies were reported to the SHCS of
which 266 were also included into MoCHiV. Thus data were
available for 266 mother-child pairs. In total, 261 women
(98.1%) had singleton pregnancies, five (1.9%) had twin ges-
tations, of which two pairs were monochorionic and three
were dichorionic. In 226 women (85%) the HIV infection
was heterosexually acquired, 29 (20.9%) were infected via
intravenous drug use and in 11 (4.9%) the aetiology was
unknown (Table 1). Type of conception was reported for all
266 pregnancies. Of these, 235 (91.1%) conceptions were
spontaneous, with no protective having been used, and the
HIV status of the partner is unknown in this data set. Five
pregnancies (2%) were achieved through infertility treatment
and 16 (6.2%) by artificial (homologous)-insemination. The
mean maternal age of women at their first prenatal visit was
32 (SD: 5.4) years. Women presented at a median gestational
age of 12.3 weeks for the first prenatal visit with a wide
range from 6 to 40 weeks. Cigarette smoking during preg-
nancy was reported by 49 women (18.4%), alcohol abuse by
22 women (8.3%) and intravenous drug abuse by 16 women
(6.0%). Ten (3.8%) women were diagnosed with a hepatitis
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Table 2 Maternal characteristics according to duration of pregnancy.
Duration of pregnancy in weeks
24q0 to 33q6 34q0 to 36q6 )37
ns19 ns53 ns194
Age at delivery (years), mean (SD) 33.3 (3.7) 33.7 (5.1) 31.6 (5.7)
Non-White ethnicity, n (%) 137 (68.4) 35 (66.0) 126 (65.0)
BMI (kg/m2), n (%)
F18 0 (0) 0 (0) 1 (0.5)
19–30 11 (57.9) 46 (86.8) 154 (79.4)
)30 4 (21.1) 5 (9.4) 21 (10.8)
Risk group for HIV infection, n (%)
Heterosexual 15 (78.9) 49 (92.5) 162 (83.5)
IV drug 3 (15.8) 3 (5.7) 23 (11.9)
Other 1 (5.3) 1 (1.9) 8 (4.1)
Smoking during pregnancy, n (%) 2 (10.5) 10 (18.7) 37 (19.1)
Drug use during pregnancy, n (%) 1 (5.3) 4 (7.5) 11 (5.7)
Any alcohol consumption, n (%) 4 (21.1) 3 (5.7) 15 (7.7)
Co-infection, n (%)
Hep B (positive Ag-HBs test) 1 (5.3) 0 (0) 9 (4.6)
Hep C (positive Anti-HCV test) 2 (10.5) 2 (3.8) 6 (3.1)
Syphilis (positive TPHA or TPPA) 1 (5.3) 0 (0) 3 (1.5)
Type of conception (%)
Spontaneous 18 (94.7) 47 (88.7) 170 (87.6)
Infertility treatment 0 (0) 2 (3.8) 1 (0.5)
Artificial insemination 0 (0) 0 (0) 2 (1.0)
Self insemination 0 (0) 2 (3.8) 14 (7.2)
Gestational age in weeks at 1st GYN visit
Mean (SD) 11.1 (5.4) 11.5 (6.0) 13.1 (7.1)
Median (IQR) 10.6 (6–25) 9.9 (7–12) 11.4 (5–40)
HIV-RNA viral load (copies/mL), ns244 (%)
-50 13 (68.4) 33 (70.2) 146 (81.6)
50–399 4 (21.1) 8 (17.0) 21 (11.7)
G400 1 (5.3) 6 (12.8) 12 (6.7)
CD4 cell count (cells/mL) ns210 (%)
-200 3 (15.8) 2 (5) 10 (6.3)
200–349 3 (15.8) 12 (30) 48 (30)
350–499 2 (10.5) 10 (25) 46 (28.8)
G500 2 (10.5) 16 (40) 56 (35)
HIV diagnosis prior to pregnancy, n (%) 15 (78.9) 45 (84.9) 139 (71.6)
During current pregnancy 4 (21.1) 8 (15.1) 55 (28.4)
Time living with HIV (years)
Median (IQR) 8.3 (2.8–14.5) 4.9 (2.4–7.9) 4.9 (2.4–9.6)
ART naive, n (%)
At conception 8 (42.1) 17 (32.1) 69 (26.2)
At delivery 0 (0) 2 (3.8) 3 (1.6)
ART class at time of delivery
NNRTI 3 (15.8) 5 (9.4) 16 (8.2)
PI non-boosted 3 (15.8) 7 (13.2) 40 (20.6)
PI boosted 11 (57.9) 26 (49.1) 89 (45.9)
Triple nucleoside/other 0 (0) 4 (7.5) 18 (9.3)
Off treatment 2 (105) 9 (17.0) 25 (12.9)
Stopped ART during pregnancy, n (%) 4 (21.1) 18 (34.0) 74 (38.1)
Reasons for stopping ART
Treatment failure 0 (0) 1 (1.9) 6 (3.1)
Toxicity 0 (0) 3 (5.7) 11 (5.7)
Patient wish 0 (0) 2 (3.8) 8 (4.1)
Doctor decision 2 (10.5) 7 (13.2) 26 (13.4)
Structured treatment interruption 0 (0) 2 (3.8) 3 (1.6)
Other 2 (10.5) 3 (5.7) 15 (7.7)
SDsstandard deviation, Hep Bshepatitis B, Hep Cshepatitis C, TPHAstreponema-pallidum-hemagglutination-assay, IQRsinterquartile
range, ARTsantiretroviral therapy; NNRTIsnon-nucleoside reverse transcriptase inhibitor.
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Table 3 Pregnancy complications after 24 weeks.
Complications after 24 weeks, ns80 (30.1%)
Preterm contractions, n (%) 42 (15.8)
Cervical shortening, n (%) 27 (10.2)
Premature rupture of membranes, n (%) 16 (6.2)
Vaginal bleeding, n (%) 7 (2.6)
Intrauterine growth retardation, n (%) 11 (4.1)
Preeclampsia or hypertension, n (%) 7 (2.6)
Gestational diabetes, n (%) 7 (2.6)
Administered drugs and cerclage
Antibiotics, n (%) 75 (28.4)
Corticosteroids, n (%) 27 (10.4)
Tocolysis, n (%) 29 (11.4)
Cerclage, n (%) 5 (2.0)
Table 4 Risk factors for pregnancy complications after 24 weeks, multivariate analysis.
Odds ratio 95% CI P-value
Maternal age (per 1 year increase) 1.08 1.02–1.15 0.01
Non-White ethnicity 0.94 0.44–1.99 0.87
Smoking during pregnancy 0.59 0.22–1.56 0.28
Drugs during pregnancy 1.71 0.45–6.45 0.43
Any co-infection* 0.72 0.27–1.92 0.51
*Hepatitis B, hepatitis C, syphilis.
CIsconfidence interval.
B co-infection, 10 (3.8%) women with hepatitis C co-infec-
tion and four (1.5%) tested positive for syphilis using trep-
onema-pallidum-hemagglutination-assay (TPHA) screening.
Results from the first positive HIV test were available for all
266 women. In 199 (74.8%) women, HIV was diagnosed
prior to pregnancy. In 67 women (25.2%), HIV infection was
diagnosed during the current pregnancy. Diagnosis of HIV
after conception was much more common among non-Cau-
casian women (83.6%) compared to Caucasian women
(16.4%) (P-0.01). At time of conception, women in the
study group had HIV for a mean of 4.9 years (IQR: 2.4–9.9)
and some cultural differences were noticeable. Non-Cauca-
sians had been diagnosed with HIV for an average of
3.1 years prior to conception compared to 8.4 years for Cau-
casians (P-0.01). This difference remained significant even
after controlling for maternal age.
The majority of women w251 (94.4%)x received ART dur-
ing pregnancy. Of those, 172 women (68.5%) were already
on ART prior to pregnancy. In 94 cases (35.5%), treatment
was started during pregnancy irrespective of CD4q cell
count in order to prevent vertical transmission (goal of an
undetectable viral load four weeks before the date of deliv-
ery); treatment was initiated mostly in the second trimester
(ns63, 67.0%) at a median gestational age of 21.6 weeks
(IQR 17.5–26.8 weeks). The most common cART regimen
included a boosted protease inhibitor wns126 (50.2%)x. It
was documented that 96 women (38.2%) intermittently dis-
continued ART at least once during pregnancy. The reasons
are shown in Table 2. Overall, only five women (1.9%) were
not on ART at the time of delivery.
The median gestational age at birth was 37.8 (IQR
36.9–38.6) weeks or 265 days of gestation. The median birth
weight was 2810 g (SD: 569). None of the children was
infected with HIV. Intrapartum intravenous zidovudine
(AZT) prophylaxis was applied during 73.9% of all deliv-
eries and 122 (93.1%) of all women continued their AZT
containing ART at specific intervals at time of delivery. In
the majority of the study population (192 women, 78.7%)
viral load at delivery was found to be -50 RNA-copies/mL.
Viral load was between 50 and 399 RNA-copies/mL in 33
(13.5%) and)400 RNA-copies/mL in only 19 cases (7.8%).
The CD4q cell count at delivery was reported to be
)500 cells/mL in 74 (35.2%) women and -200 cells/mL
in 15 (7.1%) patients.
Twenty-eight of 266 women (10.5%) had a vaginal deliv-
ery including 21 spontaneous deliveries, six vacuums and
one forceps extraction whereas 236 (88.7%) women deliv-
ered by caesarean section. In 180 cases (67.7%) the caesa-
rean section was elective, including eight caesarean sections
before 37 weeks’ gestation. Secondary caesarean section was
performed in 56 cases (21.1%) in an effort to prevent MTCT
after PROM (ns16) or preterm labour (ns40). In all wom-
en undergoing vaginal deliveries, the HIV RNA viral load
was -50 copies/mL.
Overall, 80 (30.1%) pregnancy-related complications were
reported after 24 weeks of gestation. The preterm delivery
rate was high with 72 (27.1%) women delivering before
37q0 weeks’ gestation; 19 women (7.1%) delivered before
34 weeks, of these three delivered before 30 weeks. Fifty-
three (19.9%) women delivered between 34 and 36q6
weeks (Table 3), of these eight (3%) were elective caesarean
sections without obstetrical problems. There were five twin
gestations: one delivered at 31 weeks, and four delivered
between 34 and 37 weeks by caesarean section. Singleton
preterm delivery rate was therefore 25.7% (67/261).
Preterm contractions were found in 42 cases (15.8%), cer-
vical shortening in 27 (10.2%) and PROM in 16 (6.0%)
(Table 3). Women with preterm delivery had lower CD4q
cell counts than women who delivered at term (66.7% vs.
53.4% -500/mL; Ps0.02).
The multivariable analysis for risk factors for adverse
pregnancy events (mainly preterm) after 24 weeks found no
difference for ethnicity, smoking habits, drug use and co-
infections (Table 4). Advanced maternal age was a signifi-
cant risk factor for adverse pregnancy outcome even after
adjusting for potential confounders like co-infections, BMI,
Aebi-Popp et al., Pregnancy outcome and HIV 357
Article in press - uncorrected proof
smoking habits, alcohol or drug abuse waOR: 1.06, 95% con-
fidence interval (CI) 1.01–1.12, Ps0.02x.
Discussion
In the current study, the diagnosis of HIV infection was
established during pregnancy in one out of four women
(25.2%). Similar rates of HIV diagnosis during pregnancy
were reported from other countries, including a rate of
22% in Spain and 34% in Germany w10, 11x. This reinforces
the need of universal HIV screening in pregnant women –
and those seeking pregnancy – as proposed in the national
Swiss guidelines w24x. Additionally, universal screening is
cost-effective in different settings w25x and should be
employed with the ‘‘opt out’’ strategy of testing all pregnant
women unless they explicitly refuse testing. Nevertheless,
women first diagnosed with HIV during pregnancy require
post-test counseling and treatment using a multidisciplinary
approach. Generally, women at risk should be tested for HIV
prior to conception; if seropositive, they should be advised
to conceive once their viral load is controlled in order to
protect their seronegative partners. Of note, nearly 90% of
the women in our cohort conceived after unprotected sexual
intercourse. Further, it has been described that women with
HIV risk unprotected intercourse and delay disclosure in
their relationships with the intention of becoming pregnant
w26x.
In our cohort, ART during pregnancy offered good anti-
viral control of maternal HIV infection with an undetectable
viral load in 78.7% of all women at time of delivery. The
majority of women, who were treatment naive at time of
conception, started their therapy in the second trimester
(67.0%), and 31 (33.0%) started only in the third trimester.
AZT was the principal prescribed nucleoside reverse trans-
criptase inhibitor during pregnancy and was used in 93.1%
of cases. In the recent Swiss guidelines, it is not an essential
part of cART during pregnancy w24x.
Compared to other studies w7, 14, 29x, we did not find an
increased risk of adverse pregnancy outcome including pre-
eclampsia, hypertension or gestational diabetes in HIV pos-
itive women. However, the preterm delivery rate in the Swiss
cohort was high (27%). This rate is comparable to preterm
rates of HIV infected women in Spain (29%) and in the US
(28.9%) w8, 19x. In our cohort, women delivering preterm
were of older maternal age, a risk factor known in HIV neg-
ative women w6, 23x and recently shown in a study of HIV
positive women w3x. Eight out of 266 women had a caesarean
section before 37 weeks of gestation without obvious indi-
cation. Whether the decision to perform a caesarean section
prior to term is attributable to a low tolerance for fetal risks
has to be evaluated in further studies.
Moreover, women who delivered preterm tended to have
lower CD4q cell counts. It has already been described that
low maternal CD4q cell count better predicts preterm deliv-
ery than viral load w22x. Also, Townsend et al. showed an
association between low maternal CD4q cell count
(-500 cells/mL) and prematurity (13.4% vs. 10.1%, Ps
0.02) w31x. If cART is begun and viral load is undetectable
during pregnancy, spontaneous delivery is now proposed and
AZT is not recommended for peripartum use.
Therefore, in future studies it will be important to evaluate
the influence of vaginal delivery and new antiretroviral drug
regimens on pregnancy outcome.
The strength of our study is the combination of detailed
information on pregnancy and delivery with prepregnancy
information from the SHCS. The SHCS is a large cohort
that includes 40% of all patients with HIV living in Swit-
zerland and about 70% of those with AIDS w16, 34x. Since
the majority of pregnant women are also included in the
MoCHiV w15x the results are likely to be representative of
all HIV infected women in Switzerland.
The limitations of these data are that the overall numbers
are still small and the power of the study is limited. In addi-
tion, no comparison with HIV negative women was per-
formed. The CDC stadium and nadir of CD4 cells were not
included in the analyses.
We conclude that early prenatal or prepregnancy identifi-
cation of HIV infected women remains an essential goal in
the prevention of risky conception and adverse pregnancy
outcome. Our results emphasize the importance of recom-
mending an HIV test before conception and routinely per-
forming the test in the first trimester in order to avoid
missing the diagnosis during pregnancy. Our data provide
reassurance that the risks of adverse outcomes of pregnancy
attributable to ART are low and likely outweighed by the
known benefits of such therapy during pregnancy, with the
exception of preterm delivery. Our results indicate that HIV
positive women, especially at advanced maternal age and
with lower CD4 counts should be monitored carefully in an
interdisciplinary setting during pregnancy and observed
closely for signs of preterm delivery.
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